Dorsal skin reactions to continuous topical treatment with different types of corticosteroids were histologically investigated in hairless descendants of Mexican hairless dogs. The preparations tested were prednisolone (ST-1; weak), fluocinolone acetonide (ST-2; moderate), diflucortolone valrerate (ST-3; strong), and mometasone furoate (ST-4; very strong). Grossly, the sites treated with ST-3 and ST-4 showed moderate inflammatory reactions. After completion of the corticosteroid treatment, both sites were less pigmented and had a thin texture. The severity of histologic changes in the skin was dependent on the efficacy of the corticosteroids. The epidermis was prominently thinned from 1 wk after treatment with the corticosteroids, resulting in a flat dermis-epidermis junction. By the end of the corticosteroid treatment, these lesions became progressively more severe. At 2 wk after completion of topical treatment, the epidermal thickness in the sites treated with ST-1 and ST-2 began to return to normal values, whereas the epidermis of the skin treated with ST-3 and ST-4 became thinner. At 3-4 wk after topical treatment with ST-3 and ST-4, the dermis showed hyalinization of collagen bundles. These dermatologic findings in hairless dogs are in accordance with steroid-induced skin atrophy of human beings. These results suggest that the skin of hairless dogs responds sensitively to topical corticosteroids and that these animals are a useful model for investigating the efficacy and adverse effects of cutaneous topical corticosteroids.
INTRODUCTION
Topical treatment with a variety of corticosteroids plays an important part of dermatologic therapy. Recently, many kinds of potent corticosteroids have been developed, and superpotent topical corticosteroids are commonly applied to treat psoriasis and steroid-responsive dermatoses. However, with increasing potency of topical corticoids, local side effects such as skin atrophy, telangiectasia, and steroid acne have been frequently reported (22) . Corticosteroids can be divided into different groups according to their potency (2) , and there is a correlation between clinical efficacy and the risk of side effects. To date, in regard to topical treatment with a graduated series of potent corticosteroids, there are no previous reports of their effects on the histologic structure of the skin.
In recent years, we have established a colony of hairless descendants of Mexican hairless dogs (13, 14) . This laboratory animal is used for investigation of the dermatologic toxicity of chemical substances such as agricultural chemicals (12) and all-trans-retinoic acid (11) . In this study, we investigated the effects of topical and continuous treatment with different kinds of corticosteroids on the dorsal skin of hairless descendants of Mexican hairless dogs. In addition, we examined subsequent re-bound phenomena in their epidermal and dermal morphology after withdrawal of corticosteroids.
MATERIALS AND METHODS
Dogs. Two 2-yr-old N5 hairless hybrids (1 male and 1 female) between male N4 hairless dogs and female Beagles and 2 1-yr-old N4 hairless hybrids (1 male and 1 female) between male N3 hairless dogs and female Beagles were used. Dogs were individually housed in stainless steel cages (90 X 90 X 90 cm) in an animal room controlled at 24°C ± 1 °C and 55% -!-5% relative humidity with 10-15 exchanges of 100% fresh air/hr and a 12-hr light (7 am to 7 pm), 12-hr dark (7 pm to 7 am) cycle. They were fed a commercial dry dog food (Labo D Standard, Nihon Nosan Kogyo Co., Yokohama, Japan) and water ad libitum.
Corticosteroids. The following corticosteroids were classified into 4 grades according to pharmacologic effects and were used for the present study: 0.5% prednisolone (Maruishi Seiyaku Co., Tokyo, Japan; ST-1, weak), 0.025% fluocinolone acetonide (Flucort Cream, Tanabe Seiyaku Co., Osaka, Japan; ST-2, moderate), 0.1 °/o diflucortolone valrerate (Nerisona Universal Cream, Nihon Schering AG, Osaka, Japan; ST-3, strong), and 0.1 % mometasone furoate (Fulmeta Ointment, Shionogi Co., Osaka, Japan; ST-4, very strong).
Procedures. Each corticosteroid was applied to the dorsal skin ( 10 X 10 cm) of each dog at a rate of approximately 4 ~l/cm2 ( Fig. 1 ). Each corticosteroid was topically applied with a tip of a plastic pipette to an area FIG. 1.-Skin sites examined on the dorsum of a hairless dog. 1 = 0.5% prednisolone (weak); 2 = 0.025% fluocinolone acetonide (moderate) ; 3 = 0.1 °~o diflucortolone valrerate (strong); 4 = 0.1 % mometasone furoate (very strong); 5 = untreated sites; 1'-4' = each vehicle only. on the dorsal skin. The animals were restrained for 15 min to allow the corticosteroid cream to dry and to prevent it from spreading to other skin areas. Untreated skin and the sites treated with the vehicle served as controls.
The vehicle was formulated as water in oil, in which the oil phase consisted primarily of light mineral oil. To control for regional variations in dermal histology, 4 areas of the dorsal skin were treated with the vehicle. These test procedures were repeated daily for 4 consecutive weeks.
Clinical Evaluations. Clinical observations were made before the study, daily during the steroid treatment, and for 2 wk after treatment was discontinued.
Histological Examination. Tissue specimens were obtained from both the treated and the untreated sites with a 6-mm biopsy punch (Nagatoishi Co., Tokyo, Japan) under a general anesthesia with medetomidine (Domitol, Meiji Seiyaku Co., Tokyo, Japan) 1 day before the study, at weekly intervals during treatment, and at 1 and 2 wk after treatment was discontinued. Skin specimens were fixed in 10% neutral buffered formalin, and 4-~m paraffin-embedded sections were stained with hematoxylin and eosin (H&E) and toluidine blue (TB) and by the Fontana-Masson (FM) method.
Histometric Analysis. For estimation of epidermal thickness (ET), sections were cut perpendicular to the surface. Histometric measurement of the epidermis was made on H&E-stained sections. The ET was measured for 10 sections under light microscopy, and the average was calculated.
Statistical Analysis. All values are expressed as the mean ± SD, and comparisons were evaluated with Student's t-test.
RESULTS

Clinical Features
Dogs did not show body weight changes or acute or chronic clinical signs due to systemic steroid absorption during or after treatment. Before treatment, skin pigmentation of the dogs ranged from slight to mild tan, and the skin had some spotty areas of hyperpigmentation. By the end of treatment, ST-3 and ST-4 had produced moderate inflammatory reactions in the skin. At 2 wk after completion of treatment, both the ST-3-and ST-4-treated sites were less pigmented and had a thin texture. At these sites, all 3 dogs showed effacement of spotty pigmentation. In both the untreated sites and the sites treated with ST-l, ST-2, and vehicles, there were no changes during or after treatment.
Histologic Changes
The histologic changes in the dorsal skin are listed in Tables I and II. Control (Untreated and Vehicle-Treated) Sites. Before topical treatment with the steroids, the dorsal skin of the hairless dogs consisted of 2-3 cell layers and the epidermis had some melanin deposits. Melanin granules were mainly distributed among the stratum spinosum and stratum basale. The dermis of the hairless dogs contained a small number of superficial vascular plexuses (Fig. 2 ). Such structure of the dorsal skin remained unchanged throughout this study. Steroid-Treated Sites. The severity of the histologic changes in the steroid-treated sites was dependent on the potency of the corticosteroids used. The epidermis was prominently thinner after 1 wk of treatment with all 4 corticosteroids, resulting in a flat dermis-epidermis junction ( Fig. 3 ). By the end of steroid treatment, these lesions became progressively more severe (Fig. 4 ). The stratum corneum displayed a marked &dquo;basket-weave&dquo; configuration. The thickness of the stratum comeum was not attenuated. In addition, the component cells of the epidermis were flattened and had shrunken and condensed nuclei at 4 wk after topical treatment with ST-3 and ST-4 ( Fig. 4 ). Reduction in epidermal thickness resulted not only from a flattening of epidermal cells but also from an overall decrease in number of epidermal cell layers. At 1 wk after discontinuation of topical treatment with ST and ST-2, some areas of skin exhibited hyper-and/ or parakeratosis ( Fig. 5 ). At 2 wk after discontinuation of topical treatment with ST-1 and ST-2, the thickness of the epidermis began to recover to approximately half of that at the control sites. In addition, both the number of epidermal cell layers and the size of component cells in- creased after completion of topical treatment with ST 1 and ST-2 ( Fig. 6 ). However, after completion of topical treatment with ST-3 and ST-4, the epidermis became thinner ( Fig. 7 ) and follicular papillae exhibited remarkable atrophy and sparse hairs (Fig. 8 ). The base of the ingrowth of undifferentiated epithelium consisted of a hemispheric collection of mesenchymal cells. This area resembled an anlage of a hair follicle.
The dermal architecture was also altered at 3-4 wk after topical treatment with all corticosteroids. At the control sites, the dermis was made up of thick bundles of collagens with clear spaces between the fibrils and the collagen fibers. In contrast, at the sites treated with ST-1 I and ST-2 the dermal spaces were moderately narrowed, resulting in compaction and aggregation of the fibrils and the collagen bundles. At the sites treated with ST-3 and ST-4, the dermis showed hyalinization of collagen bundles (Fig. 7) . The dermal spaces between the fibrils and the bundles were greatly diminished, resulting in a homogenized dermal matrix. After completion of topical treatment with ST-3 and ST-4, hyalinization of collagen bundles in the dermis remained unchanged. At the control sites, mesenchymal cells such as fibroblasts, macrophages, and mast cells, were sparse. During the course of top- ical treatment with all 4 corticosteroids, the number of mast cells in the dermis was not affected. In some erythematous areas induced by ST-3 and ST-4, intracomeal accumulation of foamy cells with focal destruction of underlying epidermis and inflammatory cell infiltration was found (Fig. 9 ). In other areas treated with ST-3 and ST-4, the epidermis showed marked thickening with a marked decrease in melanin pigment.
Histometric Analysis of ET
The ET decreased significantly (p < 0.01) from the first week to the fourth week after steroid treatment. ET at the ST-1-and ST-2-treated sites showed a maximal reduction of about 50% at 4 wk after treatment, and ET at the sites treated with ST-3 and ST-4 was reduced from 70 ~m at the first week to 20 ~m at the fourth week ( Fig.  10 ). By 1-2 wk after completion of ST-1 and ST-2 treatment, ET approached the values obtained before treatment. However, there remained remarkable thinning in ET at the sites treated with ST-3 and ST-4. There were no changes in ET at the control sites during this study. 
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last few decades, there has been an increasing interest in the correlation between the potency of corticosteroids and clinical side effects.
Although topical corticosteroids have anti-inflammatory effects on acute and chronic dermatoses, treatment with ST-3 and ST-4 produced conflicting histopathology data in the skin of hairless dogs. Alanie and Alanie (1) reported a 0.3% incidence of sensitivity (allergic contact dermatitis) in patients to topical steroids. Cox (3) reported 5 cases of steroid-induced dermatitis. These dermatoses seemed to be allergic contact dermatitis brought about by topical treatment with potent corticosteroids. Steroid atrophy is well described as a side effect in patients treated with topical corticosteroids, and the skin is characterized by a profound increase in transparency, with a cigarette-paper-like consistency. The characteristics of the skin are increased fragility, tearing, and bruising (&dquo;steroid purpura&dquo;). In this study, continuous topical treatment with ST-3 and ST-4 provoked skin atrophy in hairless dogs.
McKenzie and Stoughton (20) found that topical corticosteroids blanch the skin of human beings. In general, the greater the degree of blanching, the more potent the corticosteroid. Weston (25) reported that the use of top- ical corticosteroids for longer than 1 mo resulted in loss of pigmentation. A loss of cutaneous melanin pigment was observed microscopically in the dogs treated with ST-3 and ST-4 in the present study, similar to those findings in human beings.
Histologically, epidermal atrophy was observed with all the corticosteroids tested in hairless dogs. Even ST l, which is generally considered to be a relatively weak steroid, caused a prominent decrease in the number of epidermal cells and a reduction in the thickness of the epidermis. These findings revealed that topical corticosteroids, even at clinically relevant doses, had the potential to induce skin atrophy.
The histologic changes associated with steroid-induced cutaneous atrophy in humans have been described in numerous publications (8, 17, 24, 26) . More specifically, there is flattening of the dermis-epidermis junction and reduced layers of shrunken and condensed cells with loss of rete pegs. In dogs, daily treatment with diflucortolone valerate for 13-14 wk resulted in atrophy of the epidermis at the application sites in several cases (6) . Our results in hairless dogs are in accordance with the histologic findings in steroid-induced skin atrophy of human beings. This skin atrophy of hairless dogs persisted after com- pletion of treatment with ST-3 and ST-4. The skin of hairless dogs appeared to be sensitive to topical corticosteroids, depending upon the potency of the corticosteroids. The duration was the same in all treatment groups.
With continuous topical treatment with corticosteroids, the stratum corneum of hairless dogs showed hyper-and/ or parakeratosis. Treatment of human skin with steroids for 6 wk resulted in thinning of the stratum comeum, which appeared as a wispy layer of horny cells, whereas the stratum comeum of Yucatan hairless micropigs remained unchanged after similar exposure to steroids (16) . Histologic characteristics of cutaneous atrophy in human beings, Yucatan hairless micropigs, and hairless dogs are summarized in Table III. In hairless dogs, some application sites treated with ST-3 and ST-4 showed focal erythema. Histologic changes were similar to those seen in cases of contact dermatitis (10). Lavker et al (16) reported that melanocytes of Yucatan hairless micropigs were not decreased in number after treatment with corticosteroids. In hairless dogs, histologic depigmentation and focal erythema faithfully reflected the clinical status of the skin. Cutaneous atrophy is believed to result primarily from attenuation of basal keratinocytes and fibroblasts (5, 8, 9, 24, 26) and from an inhibition of collagen synthesis in human skin in vivo (4, 7, 15, 21) . Sarnstrand et al (23) reported that glucocorticoid treatment not only reduced the quantity of various glycosaminoglycans but also changed the distribution, relative proportion, and structure of connective tissue proteoglycans. These changes may contribute to hyalinization of dermal collagen bundles, which is marked at the sites treated with potent corticosteroids.
Lubach et al (18) reported that 3 wk of continuous application of a strong corticosteroid (betamethasone) caused pronounced thinning (maximally 15% of the baseline value) and that weak corticosteroids (fluprednidene and hydrocortisone) thinned the skin of adult volunteers only slightly. In addition, cessation of corticosteroid application allowed the thinned skin to recede rapidly. Luback et al (19) reported that steroid-induced dermal thinning initially developed and reached a plateau within 2 wk and that skin thickness was normalized within 2 wk after cessation of steroid treatment.
Lavker et al (16) reported that ET of Yucatan hairless micropigs showed a steady decrease and a maximal reduction of 50% after 6 wk of treatment with betamethasone. Further, within 7 days after cessation of treatment, ET was 25°7o thicker than that of controls and returned to normal values by 14 days. The corticosteroid-induced atrophy observed in the skin of hairless dogs was consistent with that found in human beings and Yucatan hairless micropigs. The time course in hairless dogs is similar to that observed in the skin of human beings and Yucatan hairless micropigs. Within 2 wk after completion of treatment with weak and moderate corticosteroids, the ET of hairless dogs approached the pretreatment baseline, demonstrating the reversibility of the steroid-induced skin atrophy. However, neither the rapid recovery nor subsequent rebound phenomena were observed after withdrawal of corticosteroids in the skin of hairless dogs treated with potent corticosteroids. The difference in the potency of the corticosteroids contributed to the delayed return to normal of the ET of hairless dogs after completion of treatment. The strong corticosteroids may affect the epidermal basal cells, which are associated with cellular proliferation. After treatment with these corticosteroids, the skin of hairless dogs became much thinner than that of human beings and Yucatan hairless micropigs. The skin of hairless dogs seemed to be more sensitive to the pharmacologic action of corticosteroids than that of human beings and Yucatan hairless micropigs.
In conclusion, the skin of hairless dogs responds sensitively to topical treatment with corticosteroids. Hairless dogs are a useful model for investigating the efficacy and adverse effects of cutaneous topical corticosteroids.
Endocrine Modulating Circumstances: Health and Environmental Perspectives
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